Show simple item record

dc.contributor.authorBaelo, Aida
dc.contributor.authorLevato, Riccardo
dc.contributor.authorJulian, Esther
dc.contributor.authorCrespo, A.
dc.contributor.authorAstola, Jose
dc.contributor.authorGavalda, Joan
dc.contributor.authorEngel López, Elisabeth
dc.contributor.authorMateos Timoneda, Miguel Ángel
dc.contributor.authorTorrents, Eduard
dc.contributor.otherUniversitat Politècnica de Catalunya. Departament de Ciència dels Materials i Enginyeria Metal·lúrgica
dc.contributor.otherInstitut de Bioenginyeria de Catalunya
dc.date.accessioned2015-10-26T13:03:13Z
dc.date.available2016-07-01T00:30:55Z
dc.date.issued2015-07-10
dc.identifier.citationBaelo, A., Levato, R., Julian, E., Crespo, A., Astola, J., Gavalda, J., Engel, E., Mateos, M., Torrents, E. Disassembling bacterial extracellular matrix with DNase-coated nanoparticles to enhance antibiotic delivery in biofilm infections. "Journal of controlled release", 10 Juliol 2015, vol. 209, p. 150-158.
dc.identifier.issn0168-3659
dc.identifier.urihttp://hdl.handle.net/2117/78233
dc.description.abstractInfections caused by biofilm-forming bacteria are a major threat to hospitalized patients and the main cause of chronic obstructive pulmonary disease and cystic fibrosis. There is an urgent necessity for novel therapeutic approaches, since current antibiotic delivery fails to eliminate biofilm-protected bacteria. In this study, ciprofloxacin-loaded poly(lactic-co-glycolic acid) nanoparticles, which were functionalized with DNase I, were fabricated using a green-solvent based method and their antibiofilm activity was assessed against Pseudomonas aeruginosa biofilms. Such nanoparticles constitute a paradigm shift in biofilm treatment, since, besides releasing ciprofloxacin in a controlled fashion, they are able to target and disassemble the biofilm by degrading the extracellular DNA that stabilize the biofilm matrix. These carriers were compared with free-soluble ciprofloxacin, and ciprofloxacin encapsulated in untreated and poly(lysine)-coated nanoparticles. DNase I-activated nanoparticles were not only able to prevent biofilm formation from planktonic bacteria, but they also successfully reduced established biofilm mass, size and living cell density, as observed in a dynamic environment in a flow cell biofilm assay. Moreover, repeated administration over three days of DNase I-coated nanoparticles encapsulating ciprofloxacin was able to reduce by 95% and then eradicate more than 99.8% of established biofilm, outperforming all the other nanoparticle formulations and the free-drug tested in this study. These promising results, together with minimal cytotoxicity as tested on J774 macrophages, allow obtaining novel antimicrobial nanoparticles, as well as provide clues to design the next generation of drug delivery devices to treat persistent bacterial infections. (C) 2015 Elsevier B.V. All rights reserved.
dc.format.extent9 p.
dc.language.isoeng
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.subjectÀrees temàtiques de la UPC::Enginyeria química
dc.subject.lcshCiprofloxacin
dc.subject.lcshBiofilms
dc.subject.otherPseudomonas aeruginosa
dc.subject.otherBiofilm
dc.subject.otherCiprofloxacin
dc.subject.otherDNase I
dc.subject.otherNanoparticles
dc.subject.othercystic-fibrosis patients
dc.subject.othernanoprecipitation method
dc.subject.otherpseudomonas-aeruginosa
dc.subject.otherpolymer nanoparticles
dc.subject.otherantimicrobial peptide
dc.subject.otherciprofloxacin
dc.subject.othermacrophages
dc.subject.otherdeposition
dc.subject.otherefficacy
dc.subject.otherdisease
dc.titleDisassembling bacterial extracellular matrix with DNase-coated nanoparticles to enhance antibiotic delivery in biofilm infections
dc.typeArticle
dc.subject.lemacEnginyeria de teixits
dc.subject.lemacBiofilms
dc.subject.lemacAntibiòtics
dc.contributor.groupUniversitat Politècnica de Catalunya. BBT - Biomaterials, Biomecànica i Enginyeria de Teixits
dc.identifier.doi10.1016/j.jconrel.2015.04.028
dc.description.peerreviewedPeer Reviewed
dc.relation.publisherversionhttp://www.sciencedirect.com/science/article/pii/S0168365915002588
dc.rights.accessOpen Access
drac.iddocument16652686
dc.description.versionPostprint (author’s final draft)
dc.contributor.covenanteeHospital Universitari Vall d'Hebron
upcommons.citation.authorBaelo, A., Levato, R., Julian, E., Crespo, A., Astola, J., Gavalda, J., Engel, E., Mateos, M., Torrents, E.
upcommons.citation.publishedtrue
upcommons.citation.publicationNameJournal of controlled release
upcommons.citation.volume209
upcommons.citation.startingPage150
upcommons.citation.endingPage158


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Except where otherwise noted, content on this work is licensed under a Creative Commons license: Attribution-NonCommercial-NoDerivs 3.0 Spain